SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as market participants keenly react to Trump's State of the Union address, with community discussion intensely focused on how the speech's rhetoric, covering economic policy, tariffs, and national sentiment, will impact overall market direction and futures activity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to widespread anticipation and highly polarized reactions to Donald Trump's State of the Union address, with community discussions fiercely debating his economic claims, controversial allegations, and potential market impact.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is actively trending following a compelling presentation by Dr. Patrick Soon-Shiong on its 'chemo-free' cancer treatment, Anktiva, fueling community optimism and strong short squeeze speculation. Investors are also closely watching for any potential mention of cancer breakthroughs during the State of the Union address, amplifying conversation around the stock's significant upward momentum.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is intensely discussed, primarily driven by heightened anticipation for pivotal Nvidia earnings, which is fueling broad tech sentiment, while also reacting to political discourse, including tariff discussions from the State of the Union address, leading to mixed community views on its immediate trajectory.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending due to intensified political and regulatory scrutiny on the healthcare sector, including a new bill introduced by senators to break up conglomerates and anticipated negative comments from a former president, sparking a polarized community debate between bearish sentiment and those identifying a long-term buying opportunity.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending due to its recent Q4 earnings beat and a rally in shares, driven by increased trading volume, with the community actively debating its high valuation multiples compared to Chipotle against its strong revenue growth, expansion plans, and perceived superior menu offerings.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as recent political commentary underscores the critical need for data centers to secure their own power, a significant bullish catalyst for the company given its extensive renewable energy infrastructure and strategic pivot to AI/HPC. The community is actively discussing high short interest and upcoming earnings, fueling speculation of a potential squeeze.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending due to strong anticipation of a significant power plant contract with Applied Digital for AI data centers, a deal that the community believes is imminent and transformative, positioning BW as a crucial "power now" solution for the rapidly expanding sector.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is highly active as investors navigate immediate market volatility stemming from President Trump's plans for new global tariffs following a Supreme Court ruling, alongside growing geopolitical concerns over escalating US-Iran tensions, all while the community closely watches for shifts in Fed policy and inflation data.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as its forward outlook pressures shares amidst ongoing software sector concerns regarding AI disruption, despite a recent earnings beat and strong AI integration. Community sentiment is divided between those who view the sell-off as a buying opportunity given activist investor backing and those who anticipate continued headwinds for enterprise software.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

Equity

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.


<ul class="summary-bullets"><li>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.</li><li>Nektar stated that patients receiving monthly and quarterly dosing regimens resulted in sustained disease control for EASI-75, EASI-90, and other indicators.</li><li>The company also noted that it observed an increase in patients who achieved EASI-100 in the 24 micrograms per kilogram dosing regimens in the monthly and quarterly time periods.</li></ul>Nektar Therapeutics Inc. (NKTR) shares rose more than 42% in Tuesday’s opening trade after the company reported positive results from its long-term atopic dermatitis trial.Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/NKTR">Nektar Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels. The NKTR stock was among the top ten trending tickers on the platform.<h2 class="st-heading-2">Nektar’s Findings In The Trial</h2>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.Nektar stated that patients receiving monthly and quarterly dosing regimens achieved sustained disease control as measured by EASI-75, EASI-90, the validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and the Itch Numerical Rating Scale (NRS) response.The company also noted an increase in patients achieving EASI-100 on the 24 micrograms per kilogram dosing regimens during the monthly and quarterly periods.EASI refers to the Eczema Area and Severity Index. It quantifies the severity and extent of eczema symptoms across body regions. EASI-75 points to a greater than or equal to 75% improvement from baseline, while EASI-90 refers to a 90% or more improvement. Similarly, EASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">Retail Gives A Thumbs Up</h2>One bullish user observed that “patience does pay off,” while adding that they are not selling the stock.<stembedurl>https://stocktwits.com/aristocks/message/644554531</stembedurl>Another user stated that there is nothing to “even remotely” criticize Nektar for, following the announcement of the trial results.<stembedurl>https://stocktwits.com/clarksonhockey/message/644552638</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up 24% year-to-date and 204% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-fisv-stock-falling-today/cZbU3sOR4Yp">Why Is FISV Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

<ul class="summary-bullets"><li>Anaphylm is Aquestive’s sublingual epinephrine film for allergic reactions.</li><li>The Anaphylm application is supported by 11 clinical studies involving 411 subjects, the company said.</li><li>Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA date on January 31, it added.</li></ul>Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that currently prevent labeling discussions on Anaphylm.Anaphylm is Aquestive’s sublingual (under the tongue) epinephrine film for allergic reactions.However, the FDA also confirmed its review of the New Drug Application (NDA) remains ongoing, and no final decision has been made.Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA (Prescription Drug User Fee Act) date on January 31, noting that delays in receiving details could impact the approval timeline. A PDUFA date is the FDA's target date to make a decision on a drug application.The Anaphylm application is supported by 11 clinical studies involving 411 subjects, demonstrating pharmacokinetics comparable to epinephrine auto-injectors and a similar safety profile, Aquestive added.“As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time. Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns. The FDA stated that the notification does not reflect a final decision on the pending application and the FDA’s review remains ongoing,” said Dan Barber, President and Chief Executive Officer of Aquestive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the strong intraday decline, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/AQST">AQST</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_2de986106b.webp" alt="AQST.jpg">Over the past year, the stock has gained 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Plug Power said it was impacted by the speed and development of hydrogen economy.

Why Did AQST Stock Plunge 40% In Pre-Market Today?

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed 

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

<ul class="summary-bullets"><li>The interim data show that ARO-INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat.</li><li>In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.</li><li>ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans.</li></ul>Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 15% in Tuesday’s premarket, after it released early data from its Phase 1/2a clinical trials of its RNA interference (RNAi) therapies, ARO-INHBE and ARO-ALK7, targeting obesity.&nbsp;The preliminary results suggest these investigational treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.<h2 class="st-heading-2">Promising Fat Reduction</h2>The interim data show that ARO-INHBE, especially when combined with tirzepatide, a GLP-1/GIP receptor co-agonist, doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared with tirzepatide alone.The findings mark the first human evidence that targeting the Activin E/ALK7 pathway could enhance weight loss beyond that achieved by existing incretin therapies. In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.On Stocktwits, retail sentiment around Arrowhead stock jumped to ‘bullish’ from ‘bearish’ territory. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_081204_png_73fc92d26b.webp" alt="ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Clinical Highlights</h2>ARO-INHBE monotherapy at week 16 led to a 9.9% reduction in visceral fat, a 38% drop in liver fat, and a 3.6% increase in lean muscle. Two doses at week 24 further improved visceral fat reduction to 15.6% after adjusting for placebo.&nbsp;Combined with tirzepatide, ARO-INHBE achieved roughly double the weight loss and triple the fat reduction compared to tirzepatide alone.ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans, reducing ALK7 mRNA in fat tissue by an average of 88% at the 200 mg dose, with a peak reduction of 94%. Early data also showed a 14.1% reduction in visceral fat after a single dose at week 8, adjusted for placebo.ARWR stock has gained over 227% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-draws-bullish-retail-chatter-ahead-of-key-investor-event-trader-calls-it-potential-multibagger/cmxwMoyR4T0">Ondas Stock Draws Bullish Retail Chatter Ahead Of Key Investor Event – Trader Calls It ‘Potential Multibagger’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

Why Did ARWR Stock Surge Over 15% Pre-Market Today? 

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.

3 Undervalued ETFs to Buy Before 2026

Worried about high valuations? KBE, XRT, and XPH with low P/Es and fresh momentum are three undervalued ETFs to consider as 2026 approaches.

Pharma ETF (XPH) Hits a New 52-Week High

Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?

SPDR Series Trust - State Street SPDR S&P Pharmaceuticals ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

XPH
SPDR Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XPH News

XPHSPDR Pharmaceuticals ETF